. Author manuscript; available in PMC: 2020 Apr 20.

Published in final edited form as: JAMA. 2015 May 26;313(20):2075–2077. doi: 10.1001/jama.2015.4559

Table 2.

Association of Aflatoxin B₁-Lysine Adducts in Patients With Gallbladder Cancer Compared With 2 Control Groups^a

	Aflatoxin B₁-Lysine Adduct
	Detection	Change in Level per 10 pg/mg of Albumin^b
Controls with gallstones vs community controls	1.4 (0.4-4.4)	0.6 (0.03-5.7)
Patients with gallbladder cancer vs controls with gallstones	9.4 (2.8-37.2)	4.0 (1.0-78.0)
Patients with gallbladder cancer vs community controls	13.2 (4.3-47.9)	2.5 (1.0-16.7)

Values are expressed as odds ratios and 95% confidence intervals from polytomous logistic regression models adjusted for at least weekly consumption of ají rojo paste. Estimates obtained using community controls as the referent group in one model and controls with gallstones as the referent group in the other model.

Restricted to individuals with detectable levels (≥0.5 pg/mg of albumin).